Phibro Animal Health Corporation
NASDAQ•PAHC
CEO: Mr. Jack Clifford Bendheim
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2014-04-11
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Contact Information
Glenpointe Centre East, 3rd Floor Suite 21 300 Frank West Burr Boulevard, Teaneck, NJ, 07666-6712, United States
201-329-7300
Market Cap
$2.04B
P/E (TTM)
22.2
13.9
Dividend Yield
1.0%
52W High
$56.30
52W Low
$16.16
52W Range
Rank34Top 27.8%
4.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q2 2026 Data
Revenue
$373.91M+0.00%
4-Quarter Trend
EPS
$0.68+0.00%
4-Quarter Trend
FCF
$8.26M+0.00%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Net Sales Jump 21% Three months net sales reached $373.910M, increasing $64.649M (21%) driven by MFA portfolio integration.
Operating Income Nearly Doubles Operating income surged 97% to $50.326M for the quarter, reflecting strong gross profit leverage.
Net Income Substantially Higher Six months net income was $53.986M, a $43.826M increase over prior period results.
Gross Margin Expansion Noted Gross margin improved 260 basis points to 35.5% of net sales for the three months ended period.
Risk Factors
Geopolitical Conflict Exposure Israeli operations account for 16% of consolidated assets and net sales, facing regional volatility risks.
Mecadox Regulatory Uncertainty Sales of Mecadox product, approximately $22M annually, face potential adverse FDA withdrawal ruling.
Increased Interest Expense Interest expense rose 31% quarterly due to higher debt levels financing the recent major acquisition.
Brazil Market Restrictions Ongoing MAPA review threatens virginiamycin use for growth promotion in key Brazilian market.
Outlook
Credit Facility Covenants Met Compliance maintained with 2024 Credit Agreement financial covenants; liquidity expected adequate for twelve months.
Acquisition Integration Drives Sales MFA portfolio contributed $174.6M revenue in six months, driving Animal Health segment growth.
Managing Interest Rate Risk Utilizing interest rate swaps and collars to hedge floating SOFR obligations through 2030.
Dividend Payments Intended Board declared $0.12 per share dividend for Q1 2026, subject to financial condition review.
Peer Comparison
Revenue (TTM)
$6.22B
$3.18B
$1.91B
Gross Margin (Latest Quarter)
103.9%
96.2%
89.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| AVDL | $2.12B | -7558.7 | -0.3% | 18.7% |
| PAHC | $2.04B | 22.2 | 30.8% | 55.0% |
| AUPH | $1.97B | 6.9 | 70.4% | 10.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.4%
Moderate Growth
4Q Net Income CAGR
9.6%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:May 5, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data